Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Effectiveness of the CellFX® nsPFA Catheter Endocardial Ablation System for the Treatment of Paroxysmal Atrial Fibrillation

NCT07018596 is registered in ClinicalTrials.gov with Pulse Biosciences, Inc. as lead sponsor.

NCT NCT07018596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07018596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Effectiveness of the CellFX® nsPFA Catheter Endocardial Ablation System for the Treatment of Paroxysmal Atrial Fibrillation
Lead sponsor
Pulse Biosciences, Inc.
Phase
Not applicable
Overall status
Recruiting
Start date
April 6, 2026
Completion date
January 31, 2028
Enrollment
215 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation paroxysmal, cardiac ablation, cardiac arrhythmia